Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease

NCT00072839 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: ALX-0600
DRUG: placebo
DRUG: teduglutide 0.05
DRUG: teduglutide 0.2 mg
DRUG: Teduglutide 0.05 dose
DRUG: teduglutide 0.1 mg dose

Sponsor

Shire